Inventor · disambiguated record
Deepak Sampath
Also filed as: SAMPATH DEEPAK
17 granted patents·23 pending applications·160 citations·filing 2001–2025
94Inventor score
Top patents by PatentIndex Score
40 records- 0196US9539251B2Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitorGENENTECH INC·Filed 2013·Granted Jan 10, 2017·24 cites·14 claims
- 0296US9107926B2Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancerGENENTECH INC·Filed 2013·Granted Aug 18, 2015·28 cites·11 claims
- 0395US11110087B2Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitorGENENTECH INC·Filed 2021·Granted Sep 7, 2021·5 cites·29 claims
- 0494US11590128B2Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitorGENENTECH INC·Filed 2022·Granted Feb 28, 2023·3 cites·7 claims
- 0594US11413282B2Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitorGENENTECH INC·Filed 2016·Granted Aug 16, 2022·4 cites·10 claims
- 0693US10993942B2Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitorGENENTECH INC·Filed 2020·Granted May 4, 2021·3 cites·30 claims
- 0792US8247397B2Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of useBELVIN MARCIA·Filed 2008·Granted Aug 21, 2012·40 cites·34 claims
- 0891US8604014B2Combinations of phosphoinositide 3-kinase inhibitor compounds chemotherapeutic agents, and methods of useBELVIN MARCIA·Filed 2011·Granted Dec 10, 2013·26 cites·15 claims
- 0990US10898570B2Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibitorGENENTECH INC·Filed 2017·Granted Jan 26, 2021·3 cites·6 claims
- 1090US2024180901A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2023·Application pending·0 cites
- 1189US2025367287A1Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitorGENENTECH INC·Filed 2025·Application pending·0 cites
- 1288US2025121058A1Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitorGENENTECH INC·Filed 2024·Application pending·0 cites
- 1388US2023255959A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2023·Application pending·0 cites
- 1487US9855270B2Methods and compositions for modulating estrogen receptor mutantsGENENTECH INC·Filed 2015·Granted Jan 2, 2018·4 cites·35 claims
- 1587US2024000776A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2023·Application pending·0 cites
- 1687US2024108616A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2023·Application pending·0 cites
- 1786US2024277838A1Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitorGENENTECH INC·Filed 2024·Application pending·0 cites
- 1884US2023226045A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2023·Application pending·0 cites
- 1983US10092567B2Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of useGENENTECH INC·Filed 2017·Granted Oct 9, 2018·3 cites·10 claims
- 2083US9150549B2Combinations of AKT inhibitor compounds and erlotinib, and methods of useNANNINI MICHELLE·Filed 2012·Granted Oct 6, 2015·6 cites·14 claims
- 2181US10959993B2Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancerGENENTECH INC·Filed 2016·Granted Mar 30, 2021·2 cites·12 claims
- 2281US2022265642A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2022·Application pending·0 cites
- 2380US9610289B2Combinations of AKT inhibitor compounds and erlotinib, and methods of useGENENTECH INC·Filed 2015·Granted Apr 4, 2017·2 cites·13 claims
- 2479US2022008413A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2021·Application pending·0 cites
- 2578US2022211696A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2021·Application pending·0 cites
- 2677US9682082B2Combinations of AKT and MEK inhibitor compounds, and methods of useLEE BRIAN·Filed 2012·Granted Jun 20, 2017·4 cites·10 claims
- 2776US2025152582A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2025·Application pending·0 cites
- 2875US9346789B2Combinations of AKT inhibitor compounds and abiraterone, and methods of useNANNINI MICHELLE·Filed 2012·Granted May 24, 2016·2 cites·21 claims
- 2973US9717730B2Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of useGENENTECH INC·Filed 2016·Granted Aug 1, 2017·1 cites·10 claims
- 3073US2021213130A1Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitorGENENTECH INC·Filed 2020·Application pending·0 cites
- 3163US2018280408A1Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancerGENENTECH INC·Filed 2018·Application pending·0 cites
- 3258US2021169865A1Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancerGENENTECH INC·Filed 2021·Application pending·0 cites
- 3356US2018280505A1Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonistsGENENTECH INC·Filed 2018·Application pending·0 cites
- 3456US2016045515A1Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancerGENENTECH INC·Filed 2015·Application pending·0 cites
- 3550US2016158360A1Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonistsGENENTECH INC·Filed 2015·Application pending·0 cites
- 3645US2004023910A1Use of cyr61 in the treatment and diagnosis of human uterine leiomyomasFiled 2001·Application pending·0 cites
- 3743US2004086504A1Cyr61 as a target for treatment and diagnosis of breast cancerFiled 2001·Application pending·0 cites
- 3839US2015258080A1Therapeutic combinations with estrogen receptor modulatorsGENENTECH INC·Filed 2015·Application pending·0 cites
- 3936US2016279142A1Combinations of a phosphoinositide 3-kinase inhibitor compound and a cdk4/6 inhibitor compound for the treatment of cancerGENENTECH INC·Filed 2016·Application pending·0 cites
- 4034US2016375033A1Methods of treatment with taselisibGENENTECH INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Deepak Sampath files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →